Nitric oxide (NO) is recognized as one of the most important cardiovascular signaling molecules, with multiple regulatory effects on myocardial and vascular tissue as well as on other tissues and organ systems. With the growth in understanding of the range and mechanisms of NO effects on the cardiovascular system, it is now possible to consider pharmaceutical interventions that directly target NO or key steps in NO effector pathways. This article reviews aspects of the cardiovascular effects of NO, abnormalities in NO regulation in heart failure, and clinical trials of drugs that target specific aspects of NO signaling pathways.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.hfc.2011.11.002 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!